APIM Therapeutics, founded in 2009 and based in Trondheim, Norway, is developing novel peptide therapeutics that target Proliferating Cell Nuclear Antigen (PCNA). Its lead candidate, ATX-101, is an anti-cancer peptide that has shown promising activity in multiple preclinical solid tumor and blood cancer models. ATX-101 has demonstrated the ability to potentiate the action of more than 15 clinical drugs. The company originated from scientific work at Prof. M. Otterlei’s laboratory at the Norwegian University of Science and Technology and is led by CEO Konstantinos Alevizopoulos. APIM plans to use the proceeds from the recent financing to advance ATX-101 toward late preclinical development. To date the company remains at the preclinical stage and has reported no public operating metrics in the article. APIM Therapeutics is an early-stage therapeutic company based in Trondheim, Norway, developing proprietary peptide drugs that target PCNA to selectively eliminate cancer cells. The company pursues synthetic lethal approaches using its peptides in combination with existing chemotherapeutic agents. Its lead compound, ATX-101, has shown promising anti-cancer activity in several blood and solid tumor models in preclinical in vitro and in vivo assays. Research underpinning the company comes from Prof. M. Otterlei and co-workers at the National Institute of Science and Technology in Trondheim. The company is led by CEO Konstantinos Alevizopoulos. APIM intends to use newly raised funds to further advance the preclinical development of ATX-101. APIM Therapeutics is a Trondheim, Norway-based early-stage therapeutic company developing proprietary peptide drugs that target PCNA. The platform stems from an original discovery by Prof. Marit Otterlei and co-inventors at NTNU. Its lead candidate, ATX-101, is being developed as a novel anti-cancer treatment aimed at modulating DNA repair and cell cycle control in tumor cells. The company intends to use the recently raised funds to pursue further in vivo testing of ATX-101. Shareholders include NTNU Technology Transfer AS and existing backer Sarsia Seed AS. The company is led by CEO Konstantinos Alevizopoulos. APIM Therapeutics AS is a spin-out from The Norwegian University of Science and Technology (NTNU). The company has developed novel peptide drugs that have the potential to improve clinical outcomes achieved with a large group of existing first-line chemotherapeutics. According to FinSMEs, APIM Therapeutics has raised NOK3.5m (approximately €440,000) from Sarsia Seed AS. Sarsia Seed is described as a Seed Capital Fund that invests in Norway-based early phase technology companies within the energy, cleantech and biotechnology/life science sectors. The article does not disclose additional operational metrics, commercialization plans, or timelines. The announcement was reported by FinSMEs on 27/05/2010.

Total raised

$1M

Funding rounds

4

Latest round

Equity

Latest activity

May 2010